We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CAH

News List

MHRA authorises Diurnal’s CAH therapy Efmody pharmatimes
July 02, 2021
Speciality pharma company Diurnal announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Efmody a marketing authorisation in Great Britain.
EC authorises Diurnal’s Efmody for CAH pharmatimes
June 02, 2021
The European Commission (EC) has approved UK-headquartered pharma company Diurnal’s Efmody for the treatment of congenital adrenal hyperplasia (CAH).
Diurnal seeks marketing authorisation for Chronocort in the UK pharmatimes
January 14, 2021
UK speciality pharma Diurnal has submitted a marketing authorisation application for Chronocort (modified-release hydrocortisone) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for patients with the rare condition congenital ...
Spruce Biosciences Announces Positive Results from Tildacerfont Study americanpharmaceuticalreview
September 23, 2019
Spruce Biosciences announced positive results from a Phase 2a, multicenter, 12-week trial of tildacerfont, an investigational, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist ...
Positive Scientific Advice from European Medicines Agency for Chronocort firstwordpharma
April 12, 2019
European Medicines Agency confirms the current clinical and regulatory path for Chronocort®...